bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0003

Order Name:
KRAS mutation-FFPE (Idylla)

 
Useful For:
Detection of 21 clinically significant KRAS mutations in codons 12 and 13 (exon 2), codons 59 and 61 (exon 3) and codons 117 and 146 (exon 4) directly from formalin-fixed paraffin-embedded (FFPE) tissue sections.
 
Methodology:
Real-time PCR (PlexZyme™ and PlexPrime™ technology, Idylla™ System)
 
AliasesName:
KRAS mutation
 
 
 
Test Code:
092-10-0003

Order Name:
KRAS mutation-FFPE (Idylla)

 
Collection Specimen Or Container:
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type:
Tissue, Formalin-fixed paraffin-embedded (FFPE) block,
2 x 10 µm FFPE tissue section, 25 – 300 mm² (≥ 10% Neoplastic cell content)
 
Sub Mission Container:
Tissue/Formalin-fixed paraffin-embedded (FFPE) block
 
Rejection Criteria:
Neoplastic cell content <10%
 
Specimen Stabillity:
Specimen Type Temperature Time
FFPE Tissue section Ambient temperature 1 month
 
 
 
Test Code:
092-10-0003

Order Name:
KRAS mutation-FFPE (Idylla)

 
Method detail:
Real-time PCR (PlexZyme™ and PlexPrime™ technology, Idylla™ System)
 
Turnaround Time:
Received specimen to reported within 3 days
 
Performing Location:
Research and Development Tel. 14252
 
Specimen Retention Time:
1 month
 
 
 
Test Code:
092-10-0003

Order Name:
KRAS mutation-FFPE (Idylla)

 
 
Clinical Information:
KRAS is one of the most frequently mutated oncogenes in human cancer, mutated in most pancreatic cancers (>90% of Pancreatic ductal adenocarcinoma) and 22-36% in lung cancer. About 45 percent of all metastatic colorectal tumors harbor mutations in exon 2, 3 and 4 of the KRAS oncogene.
 
Clinical Reference:
  1. Cox AD et al. (2014) Nature Reviews Drug Discover 13, 828–851.
  2. http://us.biocartis.com/products-kras (Retrieved 30 Jan 2019)